Printed from https://ideas.repec.org/s/spr/pharme3.html
Content
November 2020, Volume 38, Issue 11
- 1237-1245 Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome
by Edward E. Neuberger & Josh J. Carlson & David L. Veenstra - 1247-1261 Taking the Analysis of Trial-Based Economic Evaluations to the Next Level: The Importance of Accounting for Clustering
by Mohamed El Alili & Johanna M. Dongen & Keith S. Goldfeld & Martijn W. Heymans & Maurits W. Tulder & Judith E. Bosmans - 1263-1275 Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data
by Koen Degeling & Hui-Li Wong & Hendrik Koffijberg & Azim Jalali & Jeremy Shapiro & Suzanne Kosmider & Rachel Wong & Belinda Lee & Matthew Burge & Jeanne Tie & Desmond Yip & Louise Nott & Adnan Khattak & Stephanie Lim & Susan Caird & Peter Gibbs & Maarten IJzerman - 1277-1277 Correction to: Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers
by Risha Gidwani & Louise B. Russell
October 2020, Volume 38, Issue 10
- 1021-1029 Future of Data Analytics in the Era of the General Data Protection Regulation in Europe
by Katarzyna Kolasa & W. Ken Redekop & Alexander Berler & Vladimir Zah & Carl V. Asche - 1031-1042 Incorporating Pharmacometrics into Pharmacoeconomic Models: Applications from Drug Development
by Meenakshi Srinivasan & Annesha White & Ayyappa Chaturvedula & Valvanera Vozmediano & Stephan Schmidt & Leo Plouffe & La’Marcus T. Wingate - 1043-1053 Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox–Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Ben Wijnen & Nigel Armstrong & Bram Ramaekers & Willem Witlox & Marie Westwood & Debra Fayter & Steve Ryder & Titas Buksnys & Gill Worthy & Kate Misso & Sabine Grimm & Jos Kleijnen & Manuela Joore - 1055-1070 Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines
by Bogdan Grigore & Oriana Ciani & Florian Dams & Carlo Federici & Saskia Groot & Meilin Möllenkamp & Stefan Rabbe & Kosta Shatrov & Antal Zemplenyi & Rod S. Taylor - 1071-1094 Cost of Nine Pediatric Infectious Illnesses in Low- and Middle-Income Countries: A Systematic Review of Cost-of-Illness Studies
by Gatien Broucker & So Yoon Sim & Logan Brenzel & Margaret Gross & Bryan Patenaude & Dagna O. Constenla - 1095-1113 Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness
by Clara Marquina & Ella Zomer & Sandra Vargas-Torres & Sophia Zoungas & Richard Ofori-Asenso & Danny Liew & Zanfina Ademi - 1115-1121 Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US
by William V. Padula & Sonal Parasrampuria & Mariana P. Socal & Rena M. Conti & Gerard F. Anderson - 1123-1133 External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions
by Sandra Lopes & Pierre Johansen & Mark Lamotte & Phil McEwan & Anamaria-Vera Olivieri & Volker Foos - 1135-1145 Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018
by David D. Kim & Madison C. Silver & Natalia Kunst & Joshua T. Cohen & Daniel A. Ollendorf & Peter J. Neumann - 1147-1147 Correction to: Calculating and Interpreting ICERs and Net Benefit
by Mike Paulden
September 2020, Volume 38, Issue 9
- 901-903 Keeping Pace with Pharmaceutical Innovation: The Importance of the NICE Methods Review
by Paul Catchpole & Victoria Barrett - 905-911 Financing Drug Innovation in the US: Current Framework and Emerging Challenges
by David Cutler & Noam Kirson & Genia Long - 913-926 Health State Utility Values in Juvenile Idiopathic Arthritis: What is the Evidence?
by Luiza Raquel Grazziotin & Gillian Currie & Michelle M. A. Kip & Maarten J. IJzerman & Marinka Twilt & Raymond Lee & Deborah A. Marshall - 927-939 Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review
by T. Joseph Mattingly & Bryan L. Love & Bilal Khokhar - 941-951 Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States
by Sang Kyu Cho & Beenish S. Manzoor & Kavita R. Sail & Hélène Parisé & Arliene Ravelo & Sheila Shapouri & Tatyana Kapustyan & Simon Sharmokh & Suchin Virabhak & Matthew S. Davids & Scott Johnson - 953-969 Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM
by Michael Willis & Adam Fridhammar & Jens Gundgaard & Andreas Nilsson & Pierre Johansen - 971-980 Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analysis
by Jesse Elliott & Bláthnaid McCoy & Tammy Clifford & Beth K. Potter & George A. Wells & Doug Coyle - 981-994 Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria
by Thomas O’Connell & Marric Buessing & Scott Johnson & Lufei Tu & Simu K. Thomas & Ioannis Tomazos - 995-1005 Producing Standardized Country-Level Immunization Delivery Unit Cost Estimates
by Allison Portnoy & Kelsey Vaughan & Emma Clarke-Deelder & Christian Suharlim & Stephen C. Resch & Logan Brenzel & Nicolas A. Menzies - 1007-1020 Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis
by Ning Kam & Kanila Perera & Ella Zomer & Danny Liew & Zanfina Ademi
August 2020, Volume 38, Issue 8
- 777-779 Does Cost-Effectiveness Analysis Really Need to Abandon the Incremental Cost-Effectiveness Ratio to Embrace Net Benefit?
by James F. O’Mahony - 781-784 Why it’s Time to Abandon the ICER
by Mike Paulden - 785-807 Calculating and Interpreting ICERs and Net Benefit
by Mike Paulden - 809-818 Adherence to Discounting Guidelines: Evidence from Over 2000 Published Cost-Effectiveness Analyses
by Michelle Q. T. Kwok & Mistura A. Kareem & Michael J. Cash & Fiona Lafferty & Katy Tobin & James F. O’Mahony - 819-837 A Systematic Review of Methodological Variation in Healthcare Provider Perspective Tuberculosis Costing Papers Conducted in Low- and Middle-Income Settings, Using An Intervention-Standardised Unit Cost Typology
by Lucy Cunnama & Gabriela B. Gomez & Mariana Siapka & Ben Herzel & Jeremy Hill & Angela Kairu & Carol Levin & Dickson Okello & Willyanne DeCormier Plosky & Inés Garcia Baena & Sedona Sweeney & Anna Vassall & Edina Sinanovic - 839-856 Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States
by Kristina Burström & Fitsum Sebsibe Teni & Ulf-G. Gerdtham & Reiner Leidl & Gert Helgesson & Ola Rolfson & Martin Henriksson - 857-869 Estimating the Value of New Antimicrobials in the Context of Antimicrobial Resistance: Development and Application of a Dynamic Disease Transmission Model
by Jason Gordon & Oliver Darlington & Phil McEwan & Matthew Lumley & Amer Taie & Meagen Hicks & Claudie Charbonneau & Angela Blake & Neil Hawkins & Simon Goldenberg & Jonathan Otter & Mark Wilcox - 871-881 Valuing the AD-5D Dementia Utility Instrument: An Estimation of a General Population Tariff
by Tracy A. Comans & Kim-Huong Nguyen & Julie Ratcliffe & Donna Rowen & Brendan Mulhern - 883-892 Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis
by Nils-Henning Ness & Dirk Schriefer & Rocco Haase & Benjamin Ettle & Tjalf Ziemssen - 893-894 Comment on “Replacing the NCCN’s Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?”
by Wui-Jin Koh & Robert W. Carlson - 895-896 Response to Comment on “Replacing the NCCN’s Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?”
by Audrey Tran & Vinay Prasad - 897-897 Correction to: Real-World Evidence on the Patterns of Increased Societal Economic Relapse Costs in Patients with Multiple Sclerosis
by Nils-Henning Ness & Dirk Schriefer & Rocco Haase & Benjamin Ettle & Tjalf Ziemssen - 899-900 Correction to: A Systematic Review of Methodological Variation in Healthcare Provider Perspective Tuberculosis Costing Papers Conducted in Low- and Middle-Income Settings, Using An Intervention-Standardised Unit Cost Typology
by Lucy Cunnama & Gabriela B. Gomez & Mariana Siapka & Ben Herzel & Jeremy Hill & Angela Kairu & Carol Levin & Dickson Okello & Willyanne DeCormier Plosky & Inés Garcia Baena & Sedona Sweeney & Anna Vassall & Edina Sinanovic
July 2020, Volume 38, Issue 7
- 653-663 International Valuation Protocol for the EQ-5D-Y-3L
by Juan M. Ramos-Goñi & Mark Oppe & Elly Stolk & Koonal Shah & Simone Kreimeier & Oliver Rivero-Arias & Nancy Devlin - 665-681 Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations
by Matthew Franklin & James Lomas & Gerry Richardson - 683-713 Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review
by Koen Degeling & Martin Vu & Hendrik Koffijberg & Hui-Li Wong & Miriam Koopman & Peter Gibbs & Maarten IJzerman - 715-728 Economic Costs of Myasthenia Gravis: A Systematic Review
by Erik Landfeldt & Oksana Pogoryelova & Thomas Sejersen & Niklas Zethraeus & Ari Breiner & Hanns Lochmüller - 729-731 Replacing the NCCN’s Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?
by Audrey A. Tran & Vinay Prasad - 733-735 What Value Does the NCCN Affordability Rating Really Provide to Patients, Providers, and Society?
by R. Brett McQueen - 737-745 The Accuracy and Usefulness of the National Comprehensive Cancer Network Evidence Blocks Affordability Rating
by Aaron P. Mitchell & Pranammya Dey & Jennifer A. Ohn & Sara M. Tabatabai & Michael A. Curry & Peter B. Bach - 747-764 Cost-Effectiveness Analysis of Patiromer in Combination with Renin–Angiotensin–Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden
by Julia Widén & Magnus Ivarsson & Lovisa Schalin & Polina Vrouchou & Matthias Schwenkglenks & Olof Heimbürger & Zanfina Ademi & C. Simone Sutherland - 765-776 R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case Study
by Rose Hart & Darren Burns & Bram Ramaekers & Shijie Ren & Daniel Gladwell & Will Sullivan & Niall Davison & Owain Saunders & Indeg Sly & Theresa Cain & Dawn Lee
June 2020, Volume 38, Issue 6
- 527-536 Ocrelizumab for Treating Patients with Primary Progressive Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Peter Auguste & Jill Colquitt & Martin Connock & Emma Loveman & Rachel Court & Olga Ciccarelli & Carl Counsell & Xavier Armoiry - 537-555 A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway
by Huajie Jin & Paul Tappenden & Stewart Robinson & Evanthia Achilla & James H. MacCabe & David Aceituno & Sarah Byford - 557-574 ‘Mapping’ Health State Utility Values from Non-preference-Based Measures: A Systematic Literature Review in Rare Diseases
by Michela Meregaglia & Amanda Whittal & Elena Nicod & Michael Drummond - 575-591 A Comparison of the EQ-5D-3L and EQ-5D-5L
by Alexander James Thompson & Alex James Turner - 593-606 Modeling Heterogeneity in Patients’ Preferences for Psoriasis Treatments in a Multicountry Study: A Comparison Between Random-Parameters Logit and Latent Class Approaches
by Marco Boeri & Daniel Saure & Alexander Schacht & Elisabeth Riedl & Brett Hauber - 607-618 A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome
by Kelly Fust & Michael Maschio & Michele Kohli & Simron Singh & D. Mark Pritchard & Florence Marteau & Peter Myrenfors & Marion Feuilly - 619-631 Examining Approaches to Estimate the Prevalence of Catastrophic Costs Due to Tuberculosis from Small-Scale Studies in South Africa
by Sedona Sweeney & Anna Vassall & Lorna Guinness & Mariana Siapka & Natsayi Chimbindi & Don Mudzengi & Gabriela B. Gomez - 633-643 Development of Population Tariffs for the CarerQol Instrument for Hungary, Poland and Slovenia: A Discrete Choice Experiment Study to Measure the Burden of Informal Caregiving
by Petra Baji & Miklós Farkas & Dominik Golicki & Valentina Prevolnik Rupel & Renske Hoefman & Werner B. F. Brouwer & Job Exel & Zsombor Zrubka & László Gulácsi & Márta Péntek - 645-648 Comment on ‘Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal’
by Ian Jacob & Karin Butler & Karolina Badora & Vanessa Gross & Annette Beiderbeck & Steve Morris & Phil McEwan - 649-651 Response to Comment on “Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-Infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal”
by Xavier G. L. V. Pouwels & Svenja Petersohn & Vanesa Huertas Carrera & Alastair K. Denniston & Annette Chalker & Heike Raatz & Nigel Armstrong & Willem Witlox & Gill Worthy & Caro Noake & Rob Riemsma & Jos Kleijnen & Manuela A. Joore
May 2020, Volume 38, Issue 5
- 427-429 We are Not Meeting the Needs of Pharmacoeconomic Models of Nonalcoholic Steatohepatitis, But We Can
by Elliot B. Tapper & Jagpreet Chhatwal - 431-441 Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Xavier G. L. V. Pouwels & Svenja Petersohn & Vanesa Huertas Carrera & Alastair K. Denniston & Annette Chalker & Heike Raatz & Nigel Armstrong & Dhwani Shah & Willem Witlox & Gill Worthy & Caro Noake & Rob Riemsma & Jos Kleijnen & Manuela A. Joore - 443-458 Valuing Healthcare Goods and Services: A Systematic Review and Meta-Analysis on the WTA-WTP Disparity
by Adriënne H. Rotteveel & Mattijs S. Lambooij & Nicolaas P. A. Zuithoff & Job Exel & Karel G. M. Moons & G. Ardine Wit - 459-471 Systematic Literature Review of Economic Evaluations of Biological Treatment Sequences for Patients with Moderate to Severe Rheumatoid Arthritis Previously Treated with Disease-Modifying Anti-rheumatic Drugs
by Salah Ghabri & Laurent Lam & François Bocquet & Hans-Martin Spath - 473-484 Economic Evaluation of Treatments for Migraine: An Assessment of the Generalizability Following a Systematic Review
by Matteo Ruggeri & Carlo Drago & Francesco Rosiello & Valentina Orlando & Costanza Santori - 485-497 Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements
by Pierre Johansen & Daniel Howard & Ryan Bishop & Søren Ilsøe Moreno & Kristine Buchholtz - 499-513 Feasibility, Validity and Differences in Adolescent and Adult EQ-5D-Y Health State Valuation in Australia and Spain: An Application of Best–Worst Scaling
by Kim Dalziel & Max Catchpool & Borja García-Lorenzo & Inigo Gorostiza & Richard Norman & Oliver Rivero-Arias - 515-526 Healthcare Costs of Treating Privately Insured Patients with Acute Myeloid Leukemia in the United States from 2004 to 2014: A Generalized Additive Modeling Approach
by Lih-Wen Mau & Jaime M. Preussler & Linda J. Burns & Susan Leppke & Navneet S. Majhail & Christa L. Meyer & Tatenda Mupfudze & Wael Saber & Patricia Steinert & David J. Vanness
April 2020, Volume 38, Issue 4
- 317-324 Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Willem J. A. Witlox & Antoinette D. I. Asselt & Robert Wolff & Nigel Armstrong & Gill Worthy & Annette Chalker & Titas Buksnys & Lisa Stirk & Jos Kleijnen & Manuela A. Joore & Sabine E. Grimm - 325-340 Review of Valuation Methods of Preference-Based Measures of Health for Economic Evaluation in Child and Adolescent Populations: Where are We Now and Where are We Going?
by Donna Rowen & Oliver Rivero-Arias & Nancy Devlin & Julie Ratcliffe - 341-356 Cost–Utility Analyses of Interventions for Informal Carers: A Systematic and Critical Review
by Wilfried Guets & Hareth Al-Janabi & Lionel Perrier - 357-373 Preference-Based Health-Related Quality of Life Outcomes Associated with Preterm Birth: A Systematic Review and Meta-analysis
by Stavros Petrou & Natnaree Krabuanrat & Kamran Khan - 375-384 Estimating Age- and Sex-Specific Utility Values from the CHU9D Associated with Child and Adolescent BMI z-Score
by Anagha Killedar & Thomas Lung & Stavros Petrou & Armando Teixeira-Pinto & Alison Hayes - 385-395 A Case Study Examining the Usefulness of Cure Modelling for the Prediction of Survival Based on Data Maturity
by Tim S. Grant & Darren Burns & Christopher Kiff & Dawn Lee - 397-411 Determinants of Orphan Drug Prices in Germany
by Franziska Worm & Charalabos-Markos Dintsios - 413-425 A French Value Set for the EQ-5D-5L
by Luiz Flavio Andrade & Kristina Ludwig & Juan Manuel Ramos Goni & Mark Oppe & Gérard Pouvourville
March 2020, Volume 38, Issue 3
- 243-245 Reflections on NICE’s Uptake of New Methods: Past, Present, and the 2020 Review
by Meindert Boysen & Ian Watson - 247-257 After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?
by Mark Sculpher & Stephen Palmer - 259-267 Challenges of Systematic Reviews of Economic Evaluations: A Review of Recent Reviews and an Obesity Case Study
by Elisabet Jacobsen & Dwayne Boyers & Alison Avenell - 269-283 Multi-criteria Decision Analysis Software in Healthcare Priority Setting: A Systematic Review
by Alexander Moreno-Calderón & Thai S. Tong & Praveen Thokala - 285-296 Potential Bias Associated with Modeling the Effectiveness of Healthcare Interventions in Reducing Mortality Using an Overall Hazard Ratio
by Fernando Alarid-Escudero & Karen M. Kuntz - 297-306 Healthcare Expenditures for the Treatment of Patients Infected with Hepatitis C Virus in Japan
by Haruhisa Fukuda & Yoshihiko Yano & Daisuke Sato & Sachiko Ohde & Shinichi Noto & Ryo Watanabe & Osamu Takahashi - 307-313 Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic Syndrome
by Michael Ryan & Bonnie M. K. Donato & William Irish & Christoph Gasteyger & Gilbert L’Italien & Jeffrey Laurence - 315-315 Correction to: The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes
by Laura Panattoni & Paul M. Brown & Braden Te Ao & Mark Webster & Patrick Gladding
February 2020, Volume 38, Issue 2
- 125-134 Talkin’ About a Resolution: Issues in the Push for Greater Transparency of Medicine Prices
by Brendan Shaw & Jorge Mestre-Ferrandiz - 135-141 One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit
by Christopher McCabe & Mike Paulden & Isaac Awotwe & Andrew Sutton & Peter Hall - 143-158 A Review of Health Economic Studies Comparing Traditional and Massively Parallel Sequencing Diagnostic Pathways for Suspected Genetic Disorders
by Patrick Fahr & James Buchanan & Sarah Wordsworth - 159-170 Measurement Properties of Commonly Used Generic Preference-Based Measures in East and South-East Asia: A Systematic Review
by Xinyu Qian & Rachel Lee-Yin Tan & Ling-Hsiang Chuang & Nan Luo - 171-179 Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment
by David D. Kim & Gregory F. Guzauskas & Caroline S. Bennette & Anirban Basu & David L. Veenstra & Scott D. Ramsey & Josh J. Carlson - 181-192 Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada
by Feng Tian & Sherilyn K. D. Houle & Mhd. Wasem Alsabbagh & William W. L. Wong - 193-204 How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness
by Ben Kearns & John Stevens & Shijie Ren & Alan Brennan - 205-216 Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models
by Sabine E. Grimm & Xavier Pouwels & Bram L. T. Ramaekers & Ben Wijnen & Saskia Knies & Janneke Grutters & Manuela A. Joore - 217-231 Transferability of Economic Evaluations of Treatments for Advanced Melanoma
by Claire Gorry & Laura McCullagh & Michael Barry - 233-242 Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis
by T. Joseph Mattingly & Julia F. Slejko & Eberechukwu Onukwugha & Eleanor M. Perfetto & Shyamasundaran Kottilil & C. Daniel Mullins
January 2020, Volume 38, Issue 1
- 1-4 The New and Non-Transparent Cancer Drugs Fund
by Eifiona M. Wood & Dyfrig A. Hughes - 5-24 Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians
by Alisa Likhitsup & Neehar D. Parikh - 25-37 Economic Burden of Anxiety Disorders: A Systematic Review and Meta-Analysis
by Alexander Konnopka & Hannah König - 39-56 A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA
by Elizabeth Wehler & Natalie Boytsov & Claudia Nicolay & Oscar Herrera-Restrepo & Stacey Kowal - 57-68 Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study
by Dean A. Regier & David L. Veenstra & Anirban Basu & Josh J. Carlson - 69-84 Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
by Luis Hernandez & Hiroyo Kuwabara & Anshul Shah & Kaoru Yamabe & Heather Burnett & Kyle Fahrbach & Maria Koufopoulou & Ryuichi Iwakiri - 85-95 Bayesian Hierarchical Models for Meta-Analysis of Quality-of-Life Outcomes: An Application in Multimorbidity
by Susanne Schmitz & Tatjana T. Makovski & Roisin Adams & Marjan Akker & Saverio Stranges & Maurice P. Zeegers - 97-108 Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival Outcomes
by Caitlin Smare & Khalid Lakhdari & Justin Doan & John Posnett & Sukhvinder Johal - 109-119 The Value of Shorter Initial Opioid Prescriptions: A Simulation Evaluation
by Margrét V. Bjarnadóttir & David R. Anderson & Kislaya Prasad & Ritu Agarwal & D. Alan Nelson - 121-122 Comment on: ‘NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence’
by Livio Garattini & Nicholas Freemantle - 123-123 Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA
by Elizabeth Wehler & Natalie Boytsov & Claudia Nicolay & Oscar Herrera-Restrepo & Stacey Kowal
December 2019, Volume 37, Issue 12
- 1417-1419 Could or Should We Use MCDA in the French HTA Process?
by Salah Ghabri & Jean-Michel Josselin & Benoît Maux - 1421-1449 Cost Effectiveness of Transplant, Conventional Chemotherapy, and Novel Agents in Multiple Myeloma: A Systematic Review
by Shuangshuang Fu & Chi-Fang Wu & Michael Wang & David R. Lairson - 1451-1468 Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design
by Daniel M. Sugrue & Thomas Ward & Sukhvir Rai & Phil McEwan & Heleen G. M. Haalen - 1469-1483 The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments
by Fernando Antonanzas & Carmelo Juárez-Castelló & Reyes Lorente & Roberto Rodríguez-Ibeas - 1485-1494 Performance of the UKPDS Outcomes Model 2 for Predicting Death and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus from a German Population-Based Cohort
by Michael Laxy & Verena Maria Schöning & Christoph Kurz & Rolf Holle & Annette Peters & Christa Meisinger & Wolfgang Rathmann & Kristin Mühlenbruch & Katharina Kähm - 1495-1507 Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II—An Updated Analysis of SEER-Medicare Data
by Ya-Chen Tina Shih & Ying Xu & Chun-Ru Chien & Bumyang Kim & Yu Shen & Liang Li & Daniel M. Geynisman - 1509-1523 Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn’s Disease
by Heather Catt & Keith Bodger & Jamie J. Kirkham & Dyfrig A. Hughes - 1525-1536 A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost‑Effectiveness Analysis
by Sandjar Djalalov & Jaclyn Beca & Emmanuel M. Ewara & Jeffrey S. Hoch - 1537-1551 Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies
by Venediktos Kapetanakis & Thibaud Prawitz & Michael Schlichting & K. Jack Ishak & Hemant Phatak & Mairead Kearney & John W. Stevens & Agnes Benedict & Murtuza Bharmal - 1553-1553 Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review
by Dongzhe Hong & Lei Si & Minghuan Jiang & Hui Shao & Wai-kit Ming & Yingnan Zhao & Yan Li & Lizheng Shi
November 2019, Volume 37, Issue 11
- 1303-1304 Improving Transparency in Decision Models: Current Issues and Potential Solutions
by Paul Tappenden & J. Jaime Caro - 1305-1312 The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood
by Seamus Kent & Frauke Becker & Talitha Feenstra & An Tran-Duy & Iryna Schlackow & Michelle Tew & Ping Zhang & Wen Ye & Shi Lizheng & William Herman & Phil McEwan & Wendelin Schramm & Alastair Gray & Jose Leal & Mark Lamotte & Michael Willis & Andrew J Palmer & Philip Clarke - 1313-1320 Developing Open-Source Models for the US Health System: Practical Experiences and Challenges to Date with the Open-Source Value Project
by Jeroen P. Jansen & Devin Incerti & Mark T. Linthicum - 1321-1327 Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States
by Josh J. Carlson & Surrey M. Walton & Anirban Basu & Richard H. Chapman & Jonathan D. Campbell & R. Brett McQueen & Steven D. Pearson & Daniel R. Touchette & David Veenstra & Melanie D. Whittington & Daniel A. Ollendorf - 1329-1339 A Need for Change! A Coding Framework for Improving Transparency in Decision Modeling
by Fernando Alarid-Escudero & Eline M. Krijkamp & Petros Pechlivanoglou & Hawre Jalal & Szu-Yu Zoe Kao & Alan Yang & Eva A. Enns - 1341-1347 Cooking Up a Transparent Model Following a DICE Recipe
by Jörgen Möller - 1349-1354 Transparency in Health Economic Modeling: Options, Issues and Potential Solutions
by Eric Q. Wu & Zheng-Yi Zhou & Jipan Xie & Cinzia Metallo & Praveen Thokala - 1355-1369 Transparency in Decision Modelling: What, Why, Who and How?
by Christopher James Sampson & Renée Arnold & Stirling Bryan & Philip Clarke & Sean Ekins & Anthony Hatswell & Neil Hawkins & Sue Langham & Deborah Marshall & Mohsen Sadatsafavi & Will Sullivan & Edward C. F. Wilson & Tim Wrightson - 1371-1381 Can You Repeat That? Exploring the Definition of a Successful Model Replication in Health Economics
by Emma McManus & David Turner & Tracey Sach - 1383-1390 NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence
by Ash Bullement & Matthew Taylor & Sam Thomas McMordie & Errol Waters & Anthony James Hatswell - 1391-1408 TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility
by Nasuh C. Büyükkaramikli & Maureen P. M. H. Rutten-van Mölken & Johan L. Severens & Maiwenn Al - 1409-1410 Publication of Decision Model Source Code: Attitudes of Health Economics Authors
by Joanna Emerson & Rachel Bacon & Alma Kent & Peter J. Neumann & Joshua T. Cohen - 1411-1411 Correction to: Publication of Decision Model Source Code: Attitudes of Health Economics Authors
by Joanna Emerson & Rachel Bacon & Alma Kent & Peter J. Neumann & Joshua T. Cohen
October 2019, Volume 37, Issue 10
- 1195-1207 Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Sabine E. Grimm & Debra Fayter & Bram L. T. Ramaekers & Svenja Petersohn & Rob Riemsma & Nigel Armstrong & Xavier Pouwels & Willem Witlox & Caro Noake & Gillian Worthy & Jos Kleijnen & Manuela A. Joore - 1209-1217 Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Matthew Walton & Sahar Sharif & Mark Simmonds & Lindsay Claxton & Robert Hodgson - 1219-1239 Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative Review
by Xiao Zang & Emanuel Krebs & Linwei Wang & Brandon D. L. Marshall & Reuben Granich & Bruce R. Schackman & Julio S. G. Montaner & Bohdan Nosyk - 1241-1260 Cost Effectiveness of Advanced Pharmacy Services Provided in the Community and Primary Care Settings: A Systematic Review
by Dalia M. Dawoud & Alexander Haines & David Wonderling & Joanna Ashe & Jennifer Hill & Mihir Varia & Philip Dyer & Julian Bion - 1261-1276 Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations
by Jesse Elliott & Sasha Katwyk & Bláthnaid McCoy & Tammy Clifford & Beth K. Potter & Becky Skidmore & George A. Wells & Doug Coyle - 1277-1286 Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand
by Khachen Kongpakwattana & Zanfina Ademi & Thanaputt Chaiyasothi & Surakit Nathisuwan & Ella Zomer & Danny Liew & Nathorn Chaiyakunapruk - 1287-1300 Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013
by Elizabeth D. Brouwer & Anirban Basu & Kai Yeung - 1301-1302 Comment on: ‘The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study’
by Livio Garattini & Anna Padula
September 2019, Volume 37, Issue 9
- 1073-1080 Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Shijie Ren & Hazel Squires & Emma Hock & Eva Kaltenthaler & Andrew Rawdin & Constantine Alifrangis - 1081-1091 The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
by Edward Cox & Ros Wade & Mathilde Peron & Kristina Charlotte Dietz & Alison Eastwood & Stephen Palmer & Susan Griffin - 1093-1127 Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions
by Marina Treskova & Stefan M. Scholz & Alexander Kuhlmann - 1129-1138 Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations
by Mario J. N. M. Ouwens & Pralay Mukhopadhyay & Yiduo Zhang & Min Huang & Nicholas Latimer & Andrew Briggs - 1139-1153 Mapping the PedsQL™ onto the CHU9D: An Assessment of External Validity in a Large Community-Based Sample
by Christine Mpundu-Kaambwa & Gang Chen & Elisabeth Huynh & Remo Russo & Julie Ratcliffe - 1155-1163 Severity-Adjusted Probability of Being Cost Effective
by Matthijs M. Versteegh & Isaac Corro Ramos & Nasuh C. Buyukkaramikli & Amir Ansaripour & Vivian T. Reckers-Droog & Werner B. F. Brouwer - 1165-1176 Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe
by Dominik Golicki & Michał Jakubczyk & Katarzyna Graczyk & Maciej Niewada - 1177-1193 Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
by Thomas E. Delea & Xinke Zhang & Jordan Amdahl & Diana Boyko & Franziska Dirnberger & Marco Campioni & Ze Cong
August 2019, Volume 37, Issue 8
- 975-984 Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma
by Frederick W. Thielen & Nasuh C. Büyükkaramikli & Rob Riemsma & Debra Fayter & Nigel Armstrong & Ching-Yun Wei & Vanesa Huertas Carrera & Kate Misso & Gill Worthy & Jos Kleijnen & Isaac Corro Ramos - 985-993 Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal
by Becky Pennington & Shije Ren & Samantha Barton & Mariana Bacelar & Steven J. Edwards - 995-1010 Cost Effectiveness of Treatments for Diabetic Retinopathy: A Systematic Literature Review
by Nikolaos Maniadakis & Evgenia Konstantakopoulou - 1011-1027 Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic Review
by Stuart J. Wright & William G. Newman & Katherine Payne - 1029-1039 The Economic Burden of Cystic Fibrosis in Germany from a Payer Perspective
by Simon Frey & Tom Stargardt & Udo Schneider & Jonas Schreyögg - 1041-1047 A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator’s Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck
by Kim Cocks & Marta Contente & Sarah Simpson & Michael DeRosa & Fiona C. Taylor & James W. Shaw - 1049-1064 Is Reclassification of the Oral Contraceptive Pill from Prescription to Pharmacist-Only Cost Effective? Application of an Economic Evaluation Approach to Regulatory Decisions
by Mutsa Gumbie & Bonny Parkinson & Henry Cutler & Natalie Gauld & Virginia Mumford - 1065-1067 Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
by Katrine Wallace & Sandra Goble & Jeff Isaacson & Lara Maloney & Terri Cameron & Josh Bedel - 1069-1069 Correction to: Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO)
by Hui Shao & Vivian Fonseca & Charles Stoecker & Shuqian Liu & Lizheng Shi - 1071-1071 Correction to: Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia
by Mark Bounthavong & Javed Butler & Chantal M. Dolan & Jeffrey D. Dunn & Kathryn A. Fisher & Nina Oestreicher & Bertram Pitt & Paul J. Hauptman & David L. Veenstra
July 2019, Volume 37, Issue 7
- 871-877 The Curve of Optimal Sample Size (COSS): A Graphical Representation of the Optimal Sample Size from a Value of Information Analysis
by Eric Jutkowitz & Fernando Alarid-Escudero & Karen M. Kuntz & Hawre Jalal - 879-886 Autologous Chondrocyte Implantation with Chondrosphere for Treating Articular Cartilage Defects in the Knee: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Xavier Armoiry & Ewen Cummins & Martin Connock & Andrew Metcalfe & Pamela Royle & Rhona Johnston & Jeremy Rodrigues & Norman Waugh & Hema Mistry - 887-894 Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Bram L. T. Ramaekers & Rob Riemsma & Sabine Grimm & Debra Fayter & Sohan Deshpande & Nigel Armstrong & Willem Witlox & Xavier Pouwels & Steven Duffy & Gill Worthy & Jos Kleijnen & Manuela A. Joore - 895-919 A Systematic Review of Direct Cardiovascular Event Costs: An International Perspective
by Steve Ryder & Kathleen Fox & Pratik Rane & Nigel Armstrong & Ching-Yun Wei & Sohan Deshpande & Lisa Stirk & Yi Qian & Jos Kleijnen - 921-929 Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation
by Hui Shao & Shuang Yang & Vivian Fonseca & Charles Stoecker & Lizheng Shi - 931-941 Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients
by Michelle Tew & Philip Clarke & Karin Thursky & Kim Dalziel - 943-952 Economic Evaluation of the 2016 Chinese Guideline and Alternative Risk Thresholds of Initiating Statin Therapy for the Management of Atherosclerotic Cardiovascular Disease
by Yawen Jiang & Weiyi Ni - 953-962 The Cancer Drugs Fund in Practice and Under the New Framework
by Celia Sabry-Grant & Kinga Malottki & Alexander Diamantopoulos - 963-964 Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
by R. Brett McQueen & Melanie D. Whittington & Rick H. Chapman & Varun M. Kumar & Jonathan D. Campbell - 965-967 Response to ‘Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”’
by Holly Guy & Lydia Walder & Mark Fisher - 969-969 Correction to: Are Quality-Adjusted Life Years a Good Proxy Measure of Individual Capabilities?
by Paul Mark Mitchell & Sridhar Venkatapuram & Jeff Richardson & Angelo Iezzi & Joanna Coast - 971-971 Correction to: Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial
by Baptiste Leurent & Manuel Gomes & Rita Faria & Stephen Morris & Richard Grieve & James R. Carpenter - 973-973 Correction to: Different Methods for Modelling Severe Hypoglycaemic Events: Implications for Effectiveness, Costs and Health Utilities
by Edna Keeney & Dalia Dawoud & Sofia Dias
June 2019, Volume 37, Issue 6
- 743-744 Cost-Effectiveness Analysis in the Context of US Commercial Health Insurance
by Bryan Dowd & John A. Nyman - 745-752 Combining the Power of Artificial Intelligence with the Richness of Healthcare Claims Data: Opportunities and Challenges
by David Thesmar & David Sraer & Lisa Pinheiro & Nick Dadson & Razvan Veliche & Paul Greenberg - 753-762 Fulvestrant for Untreated Hormone-Receptor Positive Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Joanna Picot & Neelam Kalita & Wendy Gaisford & Petra Harris & Oluchukwu Onyimadu & Keith Cooper - 763-775 Pirfenidone for Treating Idiopathic Pulmonary Fibrosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Sarah Davis & Rachid Rafia & Christopher Carroll & Jean Hamilton & Munira Essat - 777-818 Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review
by Dongzhe Hong & Lei Si & Minghuan Jiang & Hui Shao & Wai-kit Ming & Yingnan Zhao & Yan Li & Lizheng Shi - 819-827 Estimation of Cost for Endoscopic Screening for Esophageal Cancer in a High-Risk Population in Rural China: Results from a Population-Level Randomized Controlled Trial
by Fuxiao Li & Xiang Li & Chuanhai Guo & Ruiping Xu & Fenglei Li & Yaqi Pan & Mengfei Liu & Zhen Liu & Chao Shi & Hui Wang & Minmin Wang & Hongrui Tian & Fangfang Liu & Ying Liu & Jingjing Li & Hong Cai & Li Yang & Zhonghu He & Yang Ke - 829-843 A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis
by Devin Incerti & Jeffrey R. Curtis & Jason Shafrin & Darius N. Lakdawalla & Jeroen P. Jansen - 845-865 Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden
by Santiago Zuluaga-Sanchez & Megan Teynor & Christopher Knight & Robin Thompson & Thomas Lundqvist & Mats Ekelund & Annabelle Forsmark & Adrian D. Vickers & Andrew Lloyd - 867-867 Correction to: The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study
by José Leal & Stefania Manetti & James Buchanan - 869-869 Correction to: Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Hema Mistry & Chidozie Nduka & Martin Connock & Jill Colquitt & Theodoros Mantopoulos & Emma Loveman & Renata Walewska & James Mason
May 2019, Volume 37, Issue 5
- 627-630 Beneluxa: What are the Prospects for Collective Bargaining on Pharmaceutical Prices Given Diverse Health Technology Assessment Processes?
by James F. O’Mahony - 631-643 An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis
by Matthew Franklin & James Lomas & Simon Walker & Tracey Young - 645-654 Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
by Lindsay Claxton & Joanne O’Connor & Nerys Woolacott & Kath Wright & Robert Hodgson - 655-667 Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Sabine E. Grimm & Nigel Armstrong & Bram L. T. Ramaekers & Xavier Pouwels & Shona Lang & Svenja Petersohn & Rob Riemsma & Gillian Worthy & Lisa Stirk & Janine Ross & Jos Kleijnen & Manuela A. Joore - 669-688 Cost-Effectiveness of Treatment Options for Neuropathic Pain: a Systematic Review
by Natalia Ruiz-Negrón & Jyothi Menon & Jordan B. King & Junjie Ma & Brandon K. Bellows - 689-699 Doxycycline Added to Prednisolone in Outpatient-Treated Acute Exacerbations of COPD: A Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial
by Aureliano Paolo Finch & Patricia van Velzen & Gerben ter Riet & Peter J. Sterk & Jan M. Prins & Judith E. Bosmans - 701-714 Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States
by Holly Guy & Vicki Laskier & Mark Fisher & W. Richey Neuman & Iwona Bucior & Steven Deitelzweig & Alexander T. Cohen - 715-725 EQ-5D-5L Valuation for the Malaysian Population
by Asrul Akmal Shafie & Annushiah Vasan Thakumar & Ching Jou Lim & Nan Luo & Kim Rand-Hendriksen & Faridah Aryani Md Yusof - 727-737 Modeling Covariate-Adjusted Survival for Economic Evaluations in Oncology
by Istvan M. Majer & Jean-Gabriel Castaigne & Stephen Palmer & Lucy DeCosta & Marco Campioni - 739-739 Correction to: Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
by Lindsay Claxton & Joanne O’Connor & Nerys Woolacott & Kath Wright & Robert Hodgson - 741-741 Correction to: Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case Study
by Matthew Franklin & Sarah Davis & Michelle Horspool & Wei Sun Kua & Steven Julious
April 2019, Volume 37, Issue 4
- 447-450 Advances in Methods and Novel Applications for Measuring Family Spillover Effects of Illness
by Lisa A. Prosser & Eve Wittenberg - 451-456 The Inclusion of Spillover Effects in Economic Evaluations: Not an Optional Extra
by Werner B. F. Brouwer - 457-460 Expanding the Scope of Costs and Benefits for Economic Evaluations in Health: Some Words of Caution
by Christopher McCabe - 461-473 Quantifying Family Spillover Effects in Economic Evaluations: Measurement and Valuation of Informal Care Time
by Scott D. Grosse & Jamison Pike & Rieza Soelaeman & J. Mick Tilford - 475-499 Spillover Effects on Caregivers’ and Family Members’ Utility: A Systematic Review of the Literature
by Eve Wittenberg & Lyndon P. James & Lisa A. Prosser - 501-511 Using Discrete-Choice Experiment Methods to Estimate the Value of Informal Care: The Case of Children with Intellectual Disability
by Sheena Arora & Stephen Goodall & Rosalie Viney & Stewart Einfeld - 513-530 Parental Health Spillover in Cost-Effectiveness Analysis: Evidence from Self-Harming Adolescents in England
by Sandy Tubeuf & Eirini-Christina Saloniki & David Cottrell - 531-540 The Monetary Value of Informal Care: Obtaining Pure Time Valuations Using a Discrete Choice Experiment
by Renske J. Hoefman & Job Exel & Werner B. F. Brouwer - 541-551 Parent Preferences for Health Outcomes Associated with Autism Spectrum Disorders
by Tara A. Lavelle & Milton C. Weinstein & Joseph P. Newhouse & Kerim Munir & Karen A. Kuhlthau & Lisa A. Prosser - 553-562 Economic Spillover Effects of Intensive Unpaid Caregiving
by Josephine C. Jacobs & Courtney H. Van Houtven & Terri Tanielian & Rajeev Ramchand - 563-572 Dementia Family Caregivers’ Willingness to Pay for an In-home Program to Reduce Behavioral Symptoms and Caregiver Stress
by Eric Jutkowitz & Danny Scerpella & Laura T. Pizzi & Katherine Marx & Quincy Samus & Catherine Verrier Piersol & Laura N. Gitlin - 573-583 Close-Person Spill-Overs in End-of-Life Care: Using Hierarchical Mapping to Identify Whose Outcomes to Include in Economic Evaluations
by Alastair Canaway & Hareth Al-Janabi & Philip Kinghorn & Cara Bailey & Joanna Coast - 585-596 An Examination of Downstream Effects of Bereavement on Healthcare Utilization for Surviving Spouses in a National Sample of Older Adults
by Katherine A. Ornstein & Melissa M. Garrido & Albert L. Siu & Evan Bollens-Lund & Omari-Khalid Rahman & Amy S. Kelley - 597-608 Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer’s Disease Interventions
by Pei-Jung Lin & Brittany D’Cruz & Ashley A. Leech & Peter J. Neumann & Myrlene Sanon Aigbogun & Dorothee Oberdhan & Tara A. Lavelle